Preeclampsia With Severe Features Clinical Trial
Official title:
Acute Labetalol Use in Preeclampsia Randomized Trial
The purpose of this study is to understand if administration of a personalized dose of the anti-hypertensive medication, labetalol, based on patient's body-mass index, will be more effective at controlling severe hypertension during pregnancy, compared to the current standard dosing.
The investigators seek to asses the effect of obesity (BMI>30) on severe hypertension control in patients with preeclampsia with severe features. The investigators hypothesize that successive administration of 40-60-80 mg of labetolol will reduce time to blood pressure control versus the standard dosing, 20-40-80 mg labetolol, recommended by the American College of Obstetricians and Gynecologists in 2015. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04474704 -
Use of Cheetah® Cardiac Monitoring System to Guide Discontinuation of Magnesium Sulfate in Women With Severe Preeclampsia
|
N/A | |
| Terminated |
NCT03877692 -
Acute Control of Chronic Hypertension
|
Phase 4 | |
| Completed |
NCT05096728 -
Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)
|